In a subset of patients with primary pulmonary hypertension (PPH), high doses of oral calcium-channel blockers (CCB) produce
in response to adenosine (mean reduction in resistance units, <20 percent) still had a significant reduction in pulmonary vascular resistance when treated with epoprostenol (mean, 39±14 percent; P<0.002). Conclusions. In primary pulmonary hypertension, long-term therapy with epoprostenol lowers pulmonary vascular resistance beyond the level achieved in the short term with intravenous adenosine. Epoprostenol appears to have sustained efficacy in this disorder. (N Engl J Med 1998;338:273-7)
Primary pulmonary hypertension (PPH) is a rare and hourly basis up to eight times until there is either a >20% reduction in both mPAP and PVR/TPR or the fatal condition characterised by raised pulmonary artery pressures and increased pulmonary vascular resistance. patient becomes symptomatic. This is a positive vasodilator study and the patient is a "responder". If there The estimated annual incidence is 1-2 cases per million people per year. 1 The aetiology is unknown. Although is no change in mPAP, PVR or TPR, a failure to tolerate the side effects of oral calcium channel blockers, or this disease can occur at any age, it generally affects a younger population with the mean age at diagnosis hypotension or bradycardia, the patient is classified as a "non-responder". being 36 years.
2 Women are affected more commonly than men. The median survival from time of diagnosis Acute vasodilator studies identify individuals in whom treatment with long term high dose calcium channel is 2-3 years with a five year survival of less than 40%. 3 Until recently treatments for this devastating illness blockers is appropriate. Half of the cumulative drug dose that produces a response can be administered 6-8 have concentrated on high dose calcium channel blockers, warfarin, oxygen, and transplantation. High dose hourly on a regular basis. calcium channel blockers improve symptoms and survival in a well defined population which can currently only be identified at right heart catheterisation. TreatAcute vasodilator study agents ment with continuous intravenous prostacyclin and its Even to the uninitiated, the above regime seems unanalogues is in its infancy but the initial results are very workable when high dependency bed space is at a favourable with continuing haemodynamic improvepremium. A more rapid system of assessment is needed. ment at 2-3 years.
Nebulised prostacyclin 7 and nitric oxide (NO) [8] [9] [10] and Two publications in 1998 may change the way we intravenous prostacyclin 11 and adenosine 12 have been assess and treat pulmonary hypertension.
4 5 The current used as agents in acute vasodilator studies. They are practice in pulmonary vascular units is to assess the titratable, show rapid activity, have short half lives and, vasodilator response of the pulmonary circulation and in the case of inhaled NO which is inactivated before initiate therapy. Sitbon et al presented a novel evaluation reaching the systemic circulation, are selective to the technique using inhaled nitric oxide to identify pulpulmonary circulation. More importantly, the haemomonary vasodilator "responders". 4 McLaughlin et al dynamic data are available within minutes rather than have shown that prostacyclin provides benefit over calhours. cium channel blockers when used as long term therapy.
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Acute vasodilator studies: looking for  Prostacyclin is produced by the vascular endothelium. "responders" Calcium channel blockers have stood up to scrutiny It is a potent short acting vasodilator and inhibitor of platelet aggregation which produces its vascular effects in the last 10 years in the treatment of pulmonary hypertension. Using higher doses than those used to by increasing cyclic AMP in smooth muscle cells. The half life is short (3 minutes). It can be administered via treat systemic hypertension, it has been shown that there is continued haemodynamic improvement at one year a peripheral vein for acute vasodilator studies. Acute vasodilator testing with intravenous prostain "responders", a population in whom there had been a demonstrable immediate decrease in the mean pulcyclin is accomplished using a peripheral infusion. The starting dose is 1-2.5 ng/kg/min 9 13 and is increased every monary artery pressure (mPAP) and an increase in the cardiac output (CO). 6 These acute haemodynamic 10 minutes by 1-2.5 ng/kg/min to a maximum dose of 10 ng/kg/min until there is either a reduction in mPAP responses occur in only one third of patients with PPH. It is thought that acute vasodilatation may indicate the and PVR, the side effects are intolerable, or there is no response. Prostacyclin reduces PVR and increases CO additional presence of active vasoconstriction as well as obstruction to flow secondary to remodelling in the when administered acutely to patients with PPH. 11 It may also produce an unwanted decrease in the systemic vascular wall.
Rich and Brundage 6 produced guidelines for the vascular resistance and systolic blood pressure. 14 The patient may experience chest pain, flushing sensations, assessment of acute vasodilator status which have now been accepted as the gold standard. To distinguish jaw pain, headache, and diarrhoea. Acute vasodilator testing with inhaled prostacyclin is "responders" from "non-responders" involves the positioning of a thermodilution catheter in a proximal achieved by nebulising 2 ml prostacyclin solution of known concentration (15-50 ng/kg/min) in eight litres lobar pulmonary artery. Baseline pressure studies and estimation of cardiac output are performed, allowing of oxygen for 20 minutes. 15 "Responders" are rated as previously. Nebulised prostacyclin produces greater pulmonary vascular resistance (PVR) or total pulmonary resistance (TPR) to be calculated. The patient is then decreases in mPAP and PVR than intravenous prostacyclin, although these data have not been corrected transferred to a high dependency unit with the catheter in situ and challenged with oral calcium channel blockfor equivalent drug dosing. Mikhail et al found that the haemodynamic effects of prostacyclin were temporary ers. The administration of calcium channel blockers is repeated (nifedipine 20 mg or diltiazem 60 mg) on an and reversed after 10 minutes. There were no side group.bmj.com on June 22, 2017 -Published by http://thorax.bmj.com/ Downloaded from effects reported with nebulised therapy and there was NO. Other studies have also shown NO to be safe 13 and it is a commonly used study agent in the United no significant effect on systemic arterial pressure.
States. 21 The use of calcium channel blockers in PPH is associated with considerable morbidity. 22 23 Many of the side effects experienced such as headache, nausea,  Adenosine is a naturally occurring purine nucleoside vomiting and abdominal pain are not life threatening. Fatalities, independent of the test agent used, can be and an intermediate product of adenosine trisphosphate (ATP) metabolism. It has been shown to cause rereduced by excluding patients who have high right atrial pressures from acute vasodilator testing. 24 However, laxation of human pulmonary arteries 16 but also reduces systemic vascular resistance (SVR). 17 It is more comfatal outcomes are rare (<1%). 21 Acute oral calcium channel blocker challenge is an monly used in the termination of junctional tachycardias and to block atrioventricular conduction. It has a very unwieldy tool with which to identify "responders" and there are now alternatives available. Intravenous prostashort half life (13 seconds). The side effects are short lived but include chest pain and bronchospasm, so cyclin, intravenous adenosine, nebulised prostacyclin, or inhaled NO can all be used to vasodilate the pulmonary adenosine should not be given to asthmatic subjects. In our unit we currently use peripheral venous infusions circulation and predict acute "responder" status. Of these, NO is likely to be the drug of choice because its of adenosine to assess "responder" status in the cardiac catheter suite. 18 After initial baseline studies we adeffects on the systemic circulation are short lived and not severe. minister adenosine at 50 g/kg/min and increase the rate by 50 g/kg/min every two minutes until the patient experiences symptoms such as wheezing or chest pain or there is a positive cardiovascular response. If there Long term therapy in PPH Until recently the medical treatment for pulmonary is no response the infusion is stopped at 350 g/kg/min. In an audit of 72 patients we have experienced no serious hypertension has been limited to warfarin, oxygen, and high dose calcium channel blockers for "responders" haemodynamic collapse following adenosine infusions (1998 Pulmonary Vascular Unit Audit, unpublished in association with diuretics and digoxin as required.
Anticoagulation with warfarin appears to prolong surobservation) However, patients with PPH are haemodynamically very brittle and there is always concern vival 25 and this has been attributed to the reduced risk of intravascular thrombosis. Oxygen is only useful if regarding systemic hypotension.
the patient is hypoxaemic at rest and the criteria for domiciliary oxygen in PPH are the same as for chronic obstructive pulmonary disease (COPD). 26 27 Diuretics   Nitric oxide (NO) is produced in the normal pulmonary may be useful for the oedema associated with right heart failure and with the use of high dose calcium channel artery by the enzyme nitric oxide synthase (NOS) in endothelial cells. NO diffuses into underlying vascular blockers. Intravenous prostacyclin has been used in PPH for smooth muscle cells and binds to soluble guanylate cyclase, thus stimulating the production of cyclic 3,5-more than 15 years. Due to its short lived effects in the pulmonary circulation prostacyclin needs to be admonophosphate (cGMP) which results in smooth muscle relaxation. 19 20 ministered continually through an indwelling central venous catheter. Long term therapy with continuous NO is commercially available in cylinders as pure NO and as an NO/N 2 mix. The desired concentration is intravenous prostacyclin via a Hickman line is the most effective treatment for patients with PPH who are uncontrolled using chemiluminescence and administered with air via a face mask. Sitbon et al have previously responsive to oral calcium channel blockers. 28 Patients treated show improved quality of life scores and exercise shown that inhaled NO at 10 ppm over six minutes was equivalent to intravenous prostacyclin (10 ng/kg/min) capacity.
14 Prostacyclin can be nebulised and in Japan an oral in reducing mPAP and PVR in "responders". 9 In the current paper 4 they show that NO is safer than calcium prostacyclin analogue, Beraprost, is currently being assessed for long term use. Prostacyclin has also been channel blockers for use in acute vasodilator studies in a population of 33 patients with severe PPH. They used as an antiplatelet agent in extracorporeal circulation dialysis and as a digital arteriolar vasodilator performed acute vasodilator studies first using inhaled NO at 10 ppm for 6-10 minutes and then followed the in the treatment of severe Raynaud's phenomenon.
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McLaughlin et al have now shown that continuous Rich and Brundage guidelines 6 for testing using oral calcium channel blockers. Subjects in whom there was prostacyclin infusion delays the need for transplantation and also reduces PVR in the long term. 5 In their series a reduction in mPAP and PVR were regarded as "responders". The "responders" were then given optimum of 27 patients with PPH they evaluated the acute response to adenosine. All patients were treated with doses of oral calcium channel blockers and re-catheterised at a later date.
intravenous prostacyclin via a Hickman line independent of their "responder" status. The patients The results showed that "responder" status (33%) could be identified using inhaled NO. All those who were taught how to administer the drug themselves at home. The dose of drug was increased by 2.4 ng/kg/min showed a response with calcium channel blockers responded to NO (n=9). One patient did not respond to each month until intolerance developed. The population studied had severe symptomatology and were in NYHA high dose calcium channel blockers but did respond to NO. The "responders" had a bigger response to NO class III or IV at the start of the study. The baseline mPAP was 67 mm Hg and the mean duration of treadthan to oral calcium channel blockers. The nine "responders" went on to receive oral high dose long term mill exercise was 261 seconds. Adenosine reduced the average PVR by 27% at a mean dose of 211 g/kg/ calcium channel blockers. Six patients had sustained haemodynamic improvement, two failed to respond to min. There were eight (30%) definite "non-responders" (reduction in PVR <20%). The response to adenosine long term treatment and there was one death.
Adverse effects were experienced with oral acute at the baseline catheterisation is not documented as percentage "responders". calcium channel blockers but not with inhalation of group.bmj.com on June 22, 2017 -Published by http://thorax.bmj.com/ Downloaded from LEARNING POINTS * Inhaled nitric oxide can be used acutely to predict long term response to vasodilator therapy in PPH. * Continuous long term intravenous prostacyclin improves exercise tolerance even in patients with no acute response to a vasodilator.
The patients underwent repeat cardiac catheterisation administered subcutaneously, is currently the subject of a double blind, randomised, placebo controlled, multi-12-24 months later (mean 16.5) and were stratified according to their adenosine response and their use of centre trial involving over 100 patients in the treatment arm. There have been anecdotal cases of successful long calcium channel blockers. The results were impressive. In all but one patient there was a greater than 20% term treatment with nebulised iloprost (100 g daily in five aerosols) 34 and this may merit evaluation in the reduction in PVR. Those patients who responded to adenosine had a greater fall in mPAP and PVR than future.
The field of pulmonary vascular medicine is in its the "non-responders" after long term intravenous prostacyclin therapy but even "non-responders" had siginfancy and PPH is a rare disorder, but in the last decade there has been increasing interest in the mysteries nificant haemodynamic improvement long term. Patients maintained on oral calcium channel blockers of the abnormal pulmonary circulation. It is evident that there is more research to be done if we are to prior to prostacyclin therapy derived the same benefit from additional vasodilatation long term. All patients improve further the life expectancy of a severely incapacitated young population who have this fatal disease had a subjective and objective improvement in their symptoms. Their functional NYHA class improved such of unknown aetiology. that 96% of the study population were graded as NYHA class I or II. The exercise capacity of the study popu- ers. 28 When compared with conventional treatment pro- 
